Last reviewed · How we verify
Trastuzuma
At a glance
| Generic name | Trastuzuma |
|---|---|
| Sponsor | Fudan University |
| Target | Receptor tyrosine-protein kinase erbB-2, Tubulin beta |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- HER2-positive carcinoma of breast
Common side effects
- Headache
- Nasopharyngitis
- Arthralgia
- Diarrhea
- Nausea
- Pyrexia
- Peripheral edema
- Chills
- Cough
- Back pain
- Asthenia
- Ejection fraction decreased
Serious adverse events
- Cardiac failure (congestive)
- Cardiac failure
- Interstitial pneumonitis
- Pulmonary hypertension
- Ventricular disorder
- Hypersensitivity
- Cardiac disorder
- Autoimmune thyroiditis
- Sudden death
- Asymptomatic cardiac dysfunction
Key clinical trials
- Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer
- Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trastuzuma CI brief — competitive landscape report
- Trastuzuma updates RSS · CI watch RSS
- Fudan University portfolio CI